Biotech Startups

Semarion is a University of Cambridge spin-out developing the SemaCyte platform, which converts adherent cells into barcoded, ready-to-use reagents for accelerated drug discovery and cell-based research. The platform combines materials engineering and cell biology to enable researchers to multiplex cell models and increase throughput in pharmaceutical assays.

2 investors

Semion Bio works on restoring natural pest-defense traits in crops that were lost during domestication when plants were bred for yield and size over resilience. The company operates in agricultural biotechnology focused on crop resilience against pests.

2 investors

Sorrento Therapeutics is a biotechnology and life sciences company that develops therapeutics and technologies through in-house programs, acquisitions, and mergers. Its portfolio spans areas including antibody-drug conjugates, cell therapy, and lymphatic drug delivery systems.

2 investors

Sencure designs integrated biosensor chips for wearable health monitoring and medical devices, offering signal processing and electrophysiology expertise. The company serves device manufacturers building health monitoring and wellness applications.

2 investors

SenseUP develops dsRNA-based biopesticides as an eco-friendly alternative to chemical pesticides, aimed at helping farmers protect crops from pests and pathogens. A spin-off from the German research institute FZJ, the company applies a patented dsRNA development platform for agricultural pest and disease control.

2 investors

Sensulin is a preclinical biopharmaceutical company developing glucose-responsive insulin therapies for type 1 and type 2 diabetes that aim to reduce hypoglycemia risk and daily injection requirements. The company's technology targets long-term complications of diabetes while potentially eliminating the need for separate basal and mealtime insulin dosing.

2 investors

SentreHeart appears to now redirect to AtriCure, Inc., a medical device company. Its content references products such as the cryoXT probe for reducing residual limb pain related to amputation.

2 investors

SeqOne provides a clinical genomics analysis platform for germline and somatic variant interpretation across panels, exomes, and genomes, supporting short and long-read sequencing. It offers tools such as a DiagAI variant-prioritization score and an automated data pipeline (SeqOne Flow), serving diagnostic labs and clinical genomics teams with a CE-IVD certified in vitro diagnostic medical device.

2 investors

Sequential Skin offers an end-to-end in vivo microbiome testing platform for evaluating skincare, scalp care, oral care, and intimate care products.

2 investors

Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients. It pursues scientific collaborations and licensing partnerships around its cell therapy technologies.

2 investors

Serif Biomedicines develops DNA-based therapies and nucleic acid delivery technologies for genetic medicine. The company aims to create tailored, long-acting treatments across multiple diseases.

2 investors

SFG Sciences is a drug discovery and development company focused on creating breakthrough therapeutics across various diseases. The company pursues scientific innovations to develop new drugs that improve patients' lives.

2 investors

Shionogi is a pharmaceutical company that discovers and develops medicines for challenging human diseases, including antibiotics and treatments for HIV, influenza, and COVID-19. It works to address global health challenges such as antimicrobial resistance, partnering with industry, government agencies, and early-stage biotechs.

2 investors

Shorla Oncology develops pharmaceutical products to address unmet needs in oncology. The company was founded by healthcare entrepreneurs with extensive experience in the pharmaceutical industry and regulatory affairs.

2 investors

Sigma Genetics makes devices that use magnetic fields to introduce DNA, RNA, and other charged molecules into cells, offering advantages over electroporation including reduced arcing, better scalability, and reduced invasiveness for in vivo applications. The technology targets cell therapies, cancer drug delivery, DNA vaccines, biopharmaceutical manufacturing, and cosmetics.

2 investors

Signant Health provides software platforms and clinical trial solutions for life sciences companies to manage patient-reported outcomes, evidence generation, and digital endpoints in drug development programs across multiple therapeutic areas.

2 investors

Signatur Biosciences develops molecular diagnostic solutions using qPCR technology for in vitro diagnostics, targeting clinical and laboratory markets. The company aims to deliver advanced diagnostics on widely available instrumentation to expand access to cutting-edge healthcare globally.

2 investors

Silicozyme develops customizable enzymatic toolkits for biologics refinement and general processing applications. Its enzymes are engineered for performance, stability, and resilience to serve industrial and biotech processing needs.

2 investors

SimBioSys builds AI-powered 3D visualization and diagnostic technology that models tumors as "digital twins" to support individualized cancer treatment planning. Its tools serve breast cancer surgeons and clinicians for preoperative planning and analysis in oncology.

2 investors

Simmunome provides computational biology and mechanistic modeling solutions for drug development across all phases, helping pharmaceutical companies understand disease pathways, validate drug targets, predict efficacy, and optimize patient stratification.

2 investors

Singular Medical develops implantable cardiac devices and digital health solutions for arrhythmia and heart failure management, including pacemakers, defibrillators, and remote monitoring systems. The company serves hospitals and patients in China and developing markets with products spanning screening, diagnosis, treatment, and monitoring across implant and AI domains.

2 investors

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.

2 investors

Sirius NeoSight develops a patented technology that measures cell membrane fluidity using a fluorescent molecule to detect, isolate and characterise Circulating Tumour Cells (CTCs) from blood samples. Aimed at oncologists, the technology supports early cancer detection, monitoring of recurrence and treatment resistance, and personalised therapy selection for metastatic and aggressive cancers.

2 investors

Sirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area. It focuses on drug discovery and clinical development of RNA-based medicines.

2 investors